ERBB2 and cancer: Akt/mammalian target of rapamycin (mTOR) signaling was only transiently inhibited by low doses of luteolin, which suggested that the inability to cause sustained Akt/mTOR inhibition may contribute to p21 induction and provide a survival advantage to HER2/neu-overexpressing cancer cells.